explore -WSS

explore

author：entertainment 2025-09-30 16:24:09 - browse：8

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： David Sabatini, ex

entertainment

WSS

Congress gives doctors Medicare pay bump

House looks to weaken Medicare negotiation

Morphosys mixed study results for blood cancer drug

Pfizer highlights cancer drugs it thinks could reignite investor interest

Medical device lobby: We're tired of waiting on Medicare coverage

Gain of function research would be limited under House proposal

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: A CRISPR milestone, biotech mixology

23andMe had bad news about my health. I wish a person had delivered it

Does good food count as health care? Study aims to find out

Dobbs anniversary: the lost opportunity of abortion as health care

How to address the problem of discarded donor organs

Sports medicine is finally prioritizing gender equality

Why medical students are struggling with mental health

Heart attack and stroke risk calculators need revising

Wegovy, Zepbound and weight loss drugs that preserve muscle

entertainment

CRISPR pioneers react to Casgevy, first gene

CRISPR pioneers react to Casgevy, first gene

FogPharma raises $145 million in rare Series E round

PBM reforms clear House panel

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

An inside look at PIPEs, biotech's buzzy new financing tool

hotspot

leisure time

entertainment

hotspot